FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 332:336-337 February 2, 1995 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Directly observed therapy for tuberculosis has been advocated as a way to improve compliance and control the emergence of drug resistance.^1,2 We recently cared for two patients with human immunodeficiency virus (HIV) infection who were receiving therapy under direct observation when they relapsed with drug-resistant isolates of Mycobacterium tuberculosis, presumably due to subtherapeutic drug levels caused by malabsorption.

Patient 1, a 30-year-old man, began receiving directly observed therapy in December 1993; his therapy consisted of isoniazid (300 mg), rifampin (600 mg), and pyrazinamide (800 mg) daily for ileocecal and pulmonary tuberculosis. At that time tuberculosis isolates from . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wilkins, J. J., Savic, R. M., Karlsson, M. O., Langdon, G., McIlleron, H., Pillai, G., Smith, P. J., Simonsson, U. S. H. (2008). Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption. Antimicrob. Agents Chemother. 52: 2138-2148 [Abstract] [Full Text]  
• McIlleron, H., Wash, P., Burger, A., Norman, J., Folb, P. I., Smith, P. (2006). Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.. Antimicrob. Agents Chemother. 50: 1170-1177 [Abstract] [Full Text]  
• Gurumurthy, P., Ramachandran, G., Hemanth Kumar, A. K., Rajasekaran, S., Padmapriyadarsini, C., Swaminathan, S., Bhagavathy, S., Venkatesan, P., Sekar, L., Mahilmaran, A., Ravichandran, N., Paramesh, P. (2004). Decreased Bioavailability of Rifampin and Other Antituberculosis Drugs in Patients with Advanced Human Immunodeficiency Virus Disease. Antimicrob. Agents Chemother. 48: 4473-4475 [Abstract] [Full Text]